Search Results

You are looking at 281 - 290 of 2,852 items for :

  • Refine by Access: All x
Clear All
Full access

High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex

Zheng Zhou, Alfred W. Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby-Thompson, Ann Vanderplas, Gregory A. Abel, Maria A. Rodriguez, Auayporn Nademanee, Mark S. Kaminski, Myron S. Czuczman, Michael M. Millenson, Andrew D. Zelenetz, Joyce Niland, Jonathan W. Friedberg, and Jane N. Winter

Background Results of prospective clinical trials for patients with previously untreated diffuse large B-cell lymphoma (DLBCL) suggest that patient sex, weight, and/or body mass index (BMI) impact clinical outcomes. Recent reports implicate

Full access

Volume 19 (2021): Issue Suppl_1 (Nov 2021): The Cancer Center Cessation Initiative Working Groups: Improving Oncology Care and Outcomes by Including Tobacco Treatment

Full access

CLO19-034: The Clinical Outcomes of Next-Generation Sequencing Testing at a Community Oncology Practice

Christie Hancock and Jacob Bitran

Background: The value of next-generation sequencing (NGS) tests is dependent on how it changes clinical management, if at all. There are not any guidelines on when a physician should obtain testing; what certain genetic variations can be clinically, meaningfully intervened on; and if this active drug is financially practical. A NGS test ideally should identify a targetable mutational profile that leads to a treatment that can be obtained and produces lasting responses. We reviewed the NGS testing practices at our community hospital. Methods: Patients in our oncology clinic that underwent NGS testing of their tumor were reviewed. Specifically, the patient’s age, gender, diagnosis, date of diagnosis, previous lines of treatment, date of NGS testing, and reported molecular targets were recorded. Details of the changes in clinical management based on the NGS and survival time after the NGS test was ordered were also analyzed. Results: Forty-three patient cases were reviewed that had NGS testing obtained between the years 2014–2015 and 2017. Eighteen patients were males and 25 were females. Median age was 60 years. Most common tumor type was breast; 3 were triple-negative and 6 were only hormone-receptor positive. Second most common type was colorectal. NGS changed management in 12 cases. Two patients were able to enter a clinical trial and the other 10 had therapeutic changes based on protein or mRNA overexpression. Median time of change in management to survival in these patients was 7 months. Thirty-seven patients died; overall time from ordering of test to death was 7 months. Overall time of ordering test to survival for all patients was 8 months. Conclusions: NGS gathers a significant amount of information of a patient’s cancer, but this information is difficult to interpret in the clinical setting. Twenty-eight percent of our patients had a change in treatment, but this did not translate into lasting responses compared to other patients. Furthermore, the responses that were seen may have not been related to the therapeutic interventions, but intrinsic tumor biology. It is important to be aware of the clinical utility in ordering these tests for both the physician and patient.

Full access

CLO20-050: Effect of Tumor Grade on Neoadjuvant Treatment Outcome in Esophageal Cancer

Jordan McDonald, Rutika Mehta, Sarah Hoffe, and Jose Pimiento

Full access

Counterpoint: The Case for Immediate Active Treatment

Stacy Loeb and William J. Catalona

of nonpalpable prostate cancer with curative intent: preliminary results . J Urol 2002 ; 167 : 1231 – 1234 . 8. Warlick C Trock BJ Landis P . Delayed versus immediate surgical intervention and prostate cancer outcome . J Natl Cancer

Full access

NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke, and Sandy Srinivas

carefully selected population than in patients enrolled in clinical trials. If not recognized and managed appropriately, these side effects may interfere with a patient's ability to continue on a treatment regimen, and may lead to poor outcomes or premature

Full access

Current Concepts in the Evaluation and Treatment of Patients With Diffuse Malignant Peritoneal Mesothelioma

Keli Turner, Sheelu Varghese, and H. Richard Alexander

that were independent factors associated with prolonged survival were age of 60 years or younger and complete or near-complete cytoreduction. The pathologic parameters associated with favorable outcome was absence of deep tissue invasion and a history

Full access

Single-Arm Longitudinal Study to Evaluate a Decision Aid for Women Offered Neoadjuvant Systemic Therapy for Operable Breast Cancer

Nicholas Zdenkowski, Phyllis Butow, Andrew Spillane, Charles Douglas, Kylie Snook, Mark Jones, Christopher Oldmeadow, Sheryl Fewster, Corinna Beckmore, Frances M. Boyle, and for the Australia and New Zealand Breast Cancer Trials Group

different options. DAs have been shown to help guide patients in such preference-sensitive situations and improve decision-related outcomes, including reducing decisional conflict, increasing patient knowledge, increasing their involvement in decision

Full access

Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy

Rochelle Payne Ondracek, Michael W. Kattan, Christine Murekeyisoni, Changhong Yu, Eric C. Kauffman, James R. Marshall, and James L. Mohler

diagnosis remains difficult. 2 – 5 Genetic and molecular markers for aggressive prostate cancer have improved, 6 , 7 but clinical nomograms continue to provide the most accurate tools to identify patients most likely to experience poor outcomes. 8 – 10

Full access

The Integration of Early Palliative Care With Oncology Care: The Time Has Come for a New Tradition

Jessica R. Bauman and Jennifer S. Temel

/print certificate. Release date: December 12, 2014; Expiration date: December 12, 2015 Learning Objectives Upon completion of this activity, participants will be able to: Describe the mechanisms through which early PC improves patient outcomes